Table 1 Baseline characteristics of the study cohort
Controls (n = 75) | T2DM(AF−) (n = 182) | T2DM(AF+) (n = 43) | |
|---|---|---|---|
Male, n (%) | 38 (50.7) | 102 (56.0) | 19 (44.2) |
Age (years) | 57.0 ± 11.1 | 58.2 ± 9.1 | 67.1 ± 10.7*† |
BMI (kg/m2) | 22.97 ± 2.49 | 24.35 ± 3.47* | 25.16 ± 4.06* |
BSA (kg/m2) | 1.71 ± 0.18 | 1.71 ± 0.16 | 1.68 ± 0.17 |
Heart rate (beats/min) | 71.2 ± 11.4 | 72.6 (65.2, 81.9) | 73.2 ± 14.9 |
SBP (mmHg) | 120 (106, 125) | 127 (119, 140)* | 128 (120, 143)* |
DBP (mmHg) | 74.9 ± 8.5 | 80.2 ± 10.9* | 78.6 ± 12.8 |
Diabetes duration (years) | NA | 6 (2.8, 12) | 1 (0.5, 4.5)† |
AF duration (months) | NA | NA | 2 (1,12) |
CHA(2)DS(2)-VASc score | NA | NA | 4 (2,5) |
Laboratory data | |||
FBG (mmol/L) | 5.12 (4.78, 5.73) | 7.30 (6.10, 8.95)* | 8.32 (6.44, 11.78)* |
HbA1c (%) | NA | 7.01 (6.40, 8.22) | 6.45 (6.20, 7.3)† |
Triglycerides (mmol/L) | 1.38 ± 0.57 | 1.67 ± 1.23 | 1.61 ± 1.82 |
Total cholesterol (mmol/L) | 4.51 ± 0.78 | 4.35 ± 0.96 | 3.72 ± 1.03*† |
HDL (mmol/L) | 1.36 ± 0.37 | 1.27 ± 0.40 | 1.16 ± 0.38* |
LDL (mmol/L) | 2.66 ± 0.67 | 2.59 ± 0.85 | 1.97 ± 0.77*† |
eGFR (mL/min/1.73 m2) | 88.57 ± 19.06 | 90.77 ± 18.93 | 73.69 ± 28.39*† |
Medications, n (%) | |||
Statin | NA | 49 (26.9) | 5 (11.4)† |
Biguanides | NA | 108 (59.3) | 12 (37.3)† |
Sulfonylureas | NA | 45 (24.7) | 9 (20.5) |
α-Glucosidase inhibitor | NA | 74 (40.7) | 5 (11.4)† |
Insulin | NA | 60 (33.0) | 6 (13.6)† |
ACEI/ARB | NA | 46 (25.3) | 15 (34.9) |
β-blocker | NA | 19 (10.5) | 12 (27.9)† |
Calcium channel blocker | NA | 54 (29.7) | 13 (30.2) |
Ia/Ic antiarrhythmics | NA | NA | 4 (9.3) |